Ad-hoc | 30 August 2002 07:30

aap Implantate AG english

Above-average sales, earnings and cash flow growth Ad-hoc-announcement transmitted by DGAP. The issuer is solely responsible for the content of this announcement. ——————————————————————————– Above-average sales, earnings and cash flow growth 14% sales growth / EBITDA excl. stock options up approx. 218% / Cash earnings up markedly by approx. 121% / Positive outlook for full year 2002 aap Implantate AG has succeeded in maintaining the positive trend of the first quarter in the second quarter too. First-half sales revenues were up 14% on the year to approx. EUR 7.18 million from approx. EUR 6.29 million. EBITDA excluding stock options increased by about 218% to EUR 1.95 million (previous year: EUR 615,000). Disregarding acquisition-related depreciations totaling EUR 731,000 (previous year: EUR 807,000) and stock options carried as assets totaling EUR 340,000 (previous year: EUR 415,000), EBIT amounted to approx. EUR 1.3 million and was thereby roughly EUR 1.29 million higher than the previous year’s EUR 9,000. The DVFA/SG-adjusted consolidated result for the review period was EUR 306,000 (previous year: -EUR 275,000) and DVFA/SG earnings per share were EUR 0.06 (previous year: -EUR 0.06). DVFA/SG-adjusted cash earnings totaled EUR 894,000 (previous year: EUR 352,000). Taking into account the above-mentioned special effects (stock options and acquisition-related depreciations), the figures are as follows: EBITDA increased to EUR 1.61 million (previous year: EUR 200,000), while EBIT was up markedly by EUR 1.441 million to EUR 228,000 (previous year: -EUR 1.213 million). The DVFA/SG consolidated result for the review period could be improved considerably from the previous year’s -EUR 1.02 million to -EUR 406,000. DVFA/SG earnings per share were -EUR 0.09 (previous year: -EUR 0.21), while DVFA/SG cash earnings increased by approx. 121% in the review period to EUR 912,000 (previous year: EUR 413,000). end of ad-hoc-announcement (c)DGAP 30.08.2002 Issuer’s information/explanatory remarks concerning this ad-hoc-announcement: The integration of the acquired companies has been widely completed on all levels. In view of the successful course of business in the first half, aap Implantate AG has reconfirmed its targets for the full fiscal year 2002. The company reaffirms its forecast of profitable double-digit sales growth, excluding special effects (stock options and acquisition-related depreciations) for the full year 2002. The Management Board notes that aap has positioned itself outstandingly in the orthopedics growth market on the basis of its technology competences metal implants, bone cement and cementing techniques, orthobiological materials and electro-osteostimulation processes. ——————————————————————————– WKN: 506660; ISIN: DE0005066609; Index: Listed: Neuer Markt Frankfurt; Freiverkehr in Berlin, Bremen, Düsseldorf, Hamburg, Hannover, München und Stuttgart 300730 Aug 02